A Double-Blind, Randomised, Placebo-Controlled, Parallel-Group, Multicentre, Phase II Study to Assess the Efficacy of AZD7009 (AR H065522XX) Given Intravenously (Infusion for 15 or 30 Minutes) to Patients for Conversion of Atrial Fibrillation
Phase of Trial: Phase II
Latest Information Update: 01 May 2014
At a glance
- Drugs AZD 7009 (Primary)
- Indications Atrial fibrillation
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 05 Dec 2007 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 20 Oct 2006 New trial record.